ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis

Ma, Yue; Xin, Yu; Su, Dan; Zhou, Yuxin; Li, Hongxu; Zou, Haoyi; Yu, Xuefan; Yang, Qing; Cui, Jie; Wang, Changsong*; Zhang, Yanqiao*哈尔滨医科大学
Frontiers in Oncology2022-11-24DOI: 10.3389/fonc.2022.958783
9阅读
引用收藏
分享

摘要

Introduction: We did a systematic review and meta-analysis to assess the efficacy and safety of immune checkpoint inhibitors combined with or without chemotherapies in patients with esophageal squamous cell carcinoma.Methods: Data related to the treatment of esophageal squamous cell carcinoma with immune checkpoint inhibitors therapy were retrieved from the database construction to August 2022. The risk of bias was assessed using the Cochrane Manual standard and RevMan 5.3 software for data synthesis. The outcome measures observed included overall survival, 12-month survival, disease control rate, objective response rate, treatment-related adverse events of grade 3 or higher, and progression-free survival. The adverse reactions included fatigue, diarrhea, hypothyroidism, rash, anemia, and anorexia.Results: In this meta-analysis, a total of 17 randomized controlled trials were included. In first-line therapy, immune checkpoint inhibitors combined with or without chemotherapy in the treatment of esophageal squamous cell carcinoma was more effective than chemotherapy alone. Overall survival, 12-month survival rate, and objective response rate were statistically significant. Among second-line treatments, immune checkpoint inhibitors combined with or without chemotherapy in the treatment of esophageal squamous cell carcinoma had statistically significant overall survival, 12-month survival, objective response rate, treatment-related adverse events of grade 3 or higher, and progression-free survival compared with chemotherapy alone.Conclusion: Both first- and second-line immune checkpoint inhibitors are effective for esophageal squamous cell carcinoma, and the adverse reactions are controllable and safe.

学科与关键词

关键词
immune checkpoint inhibitorsesophageal squamous cell carcinomatoxicityefficacymeta-analysis
相关
加载中…
  • Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis
    Zhang, Yangfeng; Li, Chunhui; Du, Kunpeng; Pengkhun, Nov; Huang, Zijian; Gong, Min; Li, Yanyang; Liu, Xiang; Li, Lilin; Wang, Duanyu; Wang, Changqian; Chen, Fengsheng*; Li, Jiqiang*Immunotherapy, 2023, 15(10): 737-750.被引 1
  • Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma
    Zhang, Zhengfeng; Yang, Lei; Wang, Dazhen; Ruan, Yuli; Zhang, Jianji; Zhao, Lu; Yang, Liu; Lou, Changjie*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231169981.被引 2
  • Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis
    Gao, Zhen; Huang, Shujie; Wang, Sichao; Tang, Dezhao; Xu, Wei; Zeng, Ruijie; Qiao, Guibin*LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2023, 38: 100841.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2022-11-24
卷期
第 12 卷
页码
958783
DOI
10.3389/fonc.2022.958783
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China; [82173233]

作者

  • M

    Ma, Yue (第一作者)

    harbin med univ

  • X

    Xin, Yu

    harbin med univ

查看全部 11 位作者收起作者
  • S

    Su, Dan

    harbin med univ

  • Z

    Zhou, Yuxin

    harbin med univ

  • L

    Li, Hongxu

    harbin med univ

  • Z

    Zou, Haoyi

    harbin med univ

  • Y

    Yu, Xuefan

    harbin med univ

  • Y

    Yang, Qing

    harbin med univ

  • C

    Cui, Jie

    harbin med univ

  • W

    Wang, Changsong (通讯)

    harbin med univ

  • Z

    Zhang, Yanqiao (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417